$6.67
arrow_drop_up2.30%Key Stats | |
---|---|
Open | $6.42 |
Prev. Close | $6.52 |
EPS | -1.16 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $198.62M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 6.39 | 6.88 |
52 Week Range | 3.51 | 9.96 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.16 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - Long-term Forecast to 2033
Ergebnisse aus randomisierter, doppelt verblindeter Phase-I/II-Studie von XBiotech deuten auf mögliche bahnbrechende Behandlung gegen fortgeschrittenen Bauchspeicheldrüsenkrebs hin
Les résultats de XBiotech d’une étude randomisée de phase 1/2 en double aveugle suggèrent l’émergence d’un traitement révolutionnaire potentiel contre le cancer du pancréas avancé
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma